CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 23 enrolled
Drug / intervention
Saline +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04466618
NCT04466618Phase 3Completed
CompareCT.gov

To Determine the Effect of Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

Adrian Vella·interventional·Posted Jul 10, 2020·Updated Dec 26, 2023

In Brief

A Phase 3 clinical trial evaluating Saline, Exendin-9,39, and 2 other interventions for Healthy and Type 2 Diabetes. Completed, enrolled 23 participants across 1 site.

Detailed Summary

GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes develops. The purpose of this study is to determine the effect of endogenous GLP-1 secretion on insulin secretion in people with and without type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, Type 2 Diabetes
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJul 10, 2020
Enrollment StartApr 15, 2021
Primary CompletionDec 15, 2022
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.0 years ago

Interventions

Salinebiological

Saline infused during the study

Exendin-9,39biological

Exendin-9,39 infused during the study

Saline + Intralipid/Heparinbiological

Saline infused during acute insulin resistance

Exendin-9,39 + Intralipid/Heparinbiological

Exendin-9,39 infused during acute insulin resistance